{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"34.4","value":"15.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"12.7","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Non-small cell lung cancer (NSCLC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"34.4","value":"15.0"},{"groupId":"OG002","lowerLimit":"1.6","upperLimit":"25.9","value":"9.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.0","upperLimit":"47.6","value":"26.3"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"22.6","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"Renal cell cancer (RCC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"32.5","value":"19.5"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"26.4","value":"6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Mesothelioma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"32.9","value":"14.3"},{"groupId":"OG001","lowerLimit":"0.2","upperLimit":"20.7","value":"4.8"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"19.3","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Triple negative breast cancer (TNBC)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR).\n\nFor irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters.\n\nORR is reported by tumor type.","dispersionType":"90% Confidence Interval","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"NUMBER","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From start of treatment until end of treatment, assessed up to 2.6 years","title":"Phase 2: Overall Response Rate (ORR) Per irRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}